Paper41787239
Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.
Hartung HP and 12 others. Neurol Ther, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis. Papers, record 41787239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41787239
- Disease
- multiple sclerosis symptom measurement279 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03277248 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03277261 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) | Derived from the trial | Yes | ClinicalTrials.gov |
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26121423 | Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. | Curr Med Res Opin | 2015 | https://conductscience.org/library/papers/26121423 | PubMed |
| 2 | 36452173 | Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population. | Front Neurol | 2022 | https://conductscience.org/library/papers/36452173 | PubMed |
| 3 | 34398221 | Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. | JAMA Neurol | 2021 | https://conductscience.org/library/papers/34398221 | PubMed |
| 4 | 39626127 | Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial. | Neurology | 2024 | https://conductscience.org/library/papers/39626127 | PubMed |
| 5 | 29609506 | Ublituximab for the treatment of CD20 positive B-cell malignancies. | Expert Opin Investig Drugs | 2018 | https://conductscience.org/library/papers/29609506 | PubMed |
| 6 | 34373345 | Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis. | Neurol Neuroimmunol Neuroinflamm | 2021 | https://conductscience.org/library/papers/34373345 | PubMed |
| 7 | 32530366 | Aggressive multiple sclerosis (2): Treatment. | Mult Scler | 2020 | https://conductscience.org/library/papers/32530366 | PubMed |
| 8 | 38112646 | Clinical and radiological consequences of delayed therapy escalation in patients with relapsing-remitting multiple sclerosis. | Neurol Neurochir Pol | 2024 | https://conductscience.org/library/papers/38112646 | PubMed |
| 9 | 30300457 | Multiple sclerosis - a review. | Eur J Neurol | 2019 | https://conductscience.org/library/papers/30300457 | PubMed |
| 10 | 37851189 | Multiple sclerosis: time for early treatment with high-efficacy drugs. | J Neurol | 2024 | https://conductscience.org/library/papers/37851189 | PubMed |
| 11 | 34220694 | Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry. | Front Neurol | 2021 | https://conductscience.org/library/papers/34220694 | PubMed |
| 12 | 36969208 | B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. | Front Immunol | 2023 | https://conductscience.org/library/papers/36969208 | PubMed |
| 13 | 40619726 | Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis. | Ann Clin Transl Neurol | 2025 | https://conductscience.org/library/papers/40619726 | PubMed |
| 14 | 36001711 | Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. | N Engl J Med | 2022 | https://conductscience.org/library/papers/36001711 | PubMed |
| 15 | 30820738 | Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. | J Neurol | 2019 | https://conductscience.org/library/papers/30820738 | PubMed |
| 16 | 29686116 | Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. | Neurology | 2018 | https://conductscience.org/library/papers/29686116 | PubMed |
| 17 | 33091175 | Role of B Cells in Multiple Sclerosis and Related Disorders. | Ann Neurol | 2021 | https://conductscience.org/library/papers/33091175 | PubMed |
| 18 | 35217934 | Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal. | Neurotherapeutics | 2022 | https://conductscience.org/library/papers/35217934 | PubMed |
| 19 | 26136751 | Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases. | Front Immunol | 2015 | https://conductscience.org/library/papers/26136751 | PubMed |
| 20 | 32710396 | Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study. | CNS Drugs | 2020 | https://conductscience.org/library/papers/32710396 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| UBLITUXIMAB | CHEMBL2108354 | Derived from the trial | 2 | https://conductscience.org/library/drugs/CHEMBL2108354 | ChEMBL |
| TERIFLUNOMIDE | CHEMBL973 | Derived from the trial | 2 | https://conductscience.org/library/drugs/CHEMBL973 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Cited by
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41787239
GET https://conductscience.org/api/papers/v1/41787239/references?page=2